Similar articles

• Multiple marker evaluation in prostatic cancer with prostatic acid phosphatase, gamma-seminoprotein and prostate-specific antigen.

  Fuse H, Umeda K, Mizuno I, Katayama T. Fuse H, et al. Int Urol Nephrol. 1991;23(5):455-63. doi: 10.1007/BF02583989. Int Urol Nephrol. 1991. PMID: 1718922
• [Clinical studies on tumor markers for monitoring prostate cancer patients; the evaluation of prostate-specific antigen and comparison with prostatic acid phosphatase and gamma-seminoprotein].

  Shinoda I. Shinoda I. Nihon Gan Chiryo Gakkai Shi. 1990 Nov 20;25(11):2627-39. Nihon Gan Chiryo Gakkai Shi. 1990. PMID: 1703555 Japanese.
• Serum prostatic acid phosphatase, gamma-seminoprotein and prostatic specific antigen in hemodialysis patients.

  Sasagawa I, Nakada T, Hashimoto T, Ishigooka M, Kubota Y, Hirano K, Hirano J, Suzuki Y. Sasagawa I, et al. Urol Int. 1992;48(2):181-3. doi: 10.1159/000282326. Urol Int. 1992. PMID: 1374977
• Tissue markers in the diagnosis and prognosis of prostatic carcinoma.

  de Matteis A. de Matteis A. Eur Urol. 1992;21 Suppl 1:66-70. doi: 10.1159/000474894. Eur Urol. 1992. PMID: 1385134 Review.
• Three predominant prostatic proteins.

  Abrahamsson PA, Lilja H. Abrahamsson PA, et al. Andrologia. 1990;22 Suppl 1:122-31. doi: 10.1111/j.1439-0272.1990.tb02078.x. Andrologia. 1990. PMID: 1720287 Review.